Navigation Links
Carcinoid in Medical News

The AGA Foundation awards grant to Dr. Michael Choi to further his research on carcinoid tumors

Bethesda, MD (June 25, 2009) The AGA Foundation for Digestive Health and Nutrition (FDHN) has named Michael Y. Choi , MD, the first recipient of the Mary Terese Hartzheim Award for Neuroendocrine Tumor Research. This new research award was created for young investigators interested in researching...

Lexicon Initiates Phase 2 Clinical Trial of LX2931 in Patients With Rheumatoid Arthritis

...Phase 2 clinical trials, LX1031 for irritable bowel syndrome and LX1032 for carcinoid syndrome. Furthermore, LX4211 for diabetes has recently completed dosing i...n currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which wer...

Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results

...tion of a Phase 2 study of LX1032 in patients with carcinoid syndrome," said Dr. Arthur T. Sands , president...on (FDA), into a Phase 2a study in patients with carcinoid syndrome . The Phase 2 clinical trial is designe...LX1032 and its effects on symptoms associated with carcinoid syndrome. The study will include up to 28 patient...

Carcinoid Cancer Foundation Sets Sights on Raising Awareness

...t the only cancers that catch victims by surprise. carcinoid cancer can go undetected for many years. Over 90% ...ectly diagnosed and treated for the wrong disease. carcinoid cancers are frequently diagnosed accidentally. carcinoid and related neuroendocrine tumors (NETs) grow slow...

Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results

...future upon achievement of certain milestones related to NEBIDO(R) (in development for hypogonadism) and octreotide (in development for acromegaly and carcinoid syndrome), two of the Company's primary product candidates. The acquisition will be effected by means of a tender offer for all the outstanding shares...

Frost & Sullivan Recognizes Neotropix's Approach to the Treatment of Small Cell Lung Cancer and Neuroendocrine Cancers

...o address unmet needs in the treatment of adults with small cell cancer and carcinoid cancer. It can also potentially treat children with neuroblastoma, Wilms' t...ts from Phase I/II open label clinical trials, which included both SCLC and carcinoid cancer patients, found that the majority of patients responded to NTX-010 t...

Indevus Pharmaceuticals Announces Definitive Merger Agreement With Endo Pharmaceuticals

...reotide implant (in development for acromegaly and carcinoid syndrome), two of Indevus' primary product candida...keting and sale for the treatment of acromegaly or carcinoid syndrome. The tender offer is expected to com...thogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. Abo...

Endo Pharmaceuticals to Acquire Indevus Pharmaceuticals

... for hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. About Endo Pharmaceuticals Endo Pharmaceuticals is a specialty pharmaceutical company engaged in t...

Saturated Fats Linked to Cancer of Small Intestine

...ective study to examine the association between meat and fat intake and cancer of the small intestine. During the study, 60 adenocarcinomas and 80 carcinoid tumors of the small intestine were diagnosed among the participants, and an elevated risk for these cancers was associated with saturated fat intake, ...

Also in the Sept. 9 JNCI

...144 Experts Call for Renewed Efforts in Gastroenteropancreatic Neuroendocrine Tumors During a September 2007 summit on neuroendocrine and carcinoid tumor, clinicians and researchers presented the current standards of care and identified key areas that require investigation and development. Ove...
Carcinoid in Medical Technology

Lexicon's Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA

THE WOODLANDS, Texas, July 21 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has received orphan d...

Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting

THE WOODLANDS, Texas, March 5 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that Dr. Philip Brown , senior vice president of clinical develop...

Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients

NEW YORK, Aug. 9 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and inflammatory diseases, announced today the addition of two sites to its Phase II clinical trial of Atiprimod to treat low to inter...

Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types

...ning tumors (i.e., tumors that are associated with carcinoid syndrome due to the secretion of various hormones ...iarrhea/flushing episodes associated with advanced carcinoid tumors and profuse watery diarrhea associated with... used to treat symptoms associated with metastatic carcinoid tumors (flushing and diarrhea) and vasoactive inte...

Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results

...ood and Drug Administration (FDA), into a Phase 2a study in patients with carcinoid syndrome . Lexicon has identified the clinical trial sites for this study...n currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which wer...

FDA Accepts Complete Response Submission to New Drug Application for NEBIDO(R)

... for hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. Safe Harbor Statement This press release contains forward-looking statements within the mean...

Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study

... for hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. PRO 2000 PRO 2000 (a naphthalene sulfonate polymer) is under development as a topical vaginal micr...

New Study First to Confirm Sandostatin LAR(R) Depot Controls Tumor Growth in Patients With Rare Gastrointestinal Tumors

...etween the endocrine (hormonal) system and the nervous system, and includes carcinoid tumors and pancreatic NETs. Treatment options for patients with NETs are li...utes, octreotide has been used to treat symptoms associated with metastatic carcinoid tumors (flushing and diarrhea) and vasoactive intestinal peptide (VIP) secr...

RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors

...AR Depot therapy on survival in pancreatic NET and carcinoid patients EAST HAN... mixture of tumors that include pancreatic NET and carcinoid tumors. The development of NET is not completely u...to treat the diarrhea and flushing associated with carcinoid syndrome. The active ingredient in Sandostatin L...

Callisto Pharmaceuticals Completes Enrollment of Phase II Trial of Atiprimod in Neuroendocrine Cancer

... the debilitating symptoms of this disease. About carcinoid Cancer carcinoid tumors, or carcinoids, originate in hormone-produc...h the number increasing over the past 20-30 years. carcinoid tumors that metastasize to the liver have a poor p...
Carcinoid in Medical Definition

Pathology

...ome - 5-alpha-reductase deficiency - Hypogonadism - Delayed puberty - Precocious puberty Other Autoimmune polyendocrine syndrome - carcinoid syndrome - Laron syndrome - Psychogenic dwarfism - Androgen insensitivity syndrome - Progeria v • d • e Nut...
Carcinoid in Medical Dictionary

Lung tumor

...r ... What Are the Key Statistics About Lung carcinoid Tumor ? ... to suspect you may have a lung carcinoid tumor , your doctor will use one or more ... ...s into adjacent tissues and ... Symptoms of a carcinoid lung tumor include coughing up blood, wheezing...

Gastrointestinal

...r, Fox Chase Cancer Center offers comprehensive care Gastrointestinal carcinoid tumors develop from a certain type of hormone -making ... A gastrointestinal carcinoid tumor may also produce hormones. ... Gastrointestinal bleeding inf...

Carcinoid tumor

... carcinoid is a slow-growing type of neuroendocrine tumour, ... in the cells of the neuroendocrine system. carcinoid tumors produce the vasoactive substance, serotonin. ... carcinoid tumors arising in the bronchi may be associa...

Carcinoid syndrome

... Other components of the carcinoid syndrome are diarrhea (probably caused by ... Patients with carcinoid syndrome usually excrete >25 mg of 5-HIAA per day. ... Learn about carcinoid syndrome , get support, and find treatment opt...
Carcinoid in Biological News

Society of Interventional Radiology Foundation awards $191,000 in grants

...nu Gaur, Harvard Medical School, Boston, Mass., "Hepatic Arterial Chemoembolization (HACE), Yttrium-90 Radioembolization and Drug-eluting Bead-HACE in carcinoid Metastases to the Liver." ...
Carcinoid in Biological Technology

Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome

THE WOODLANDS, Texas, July 7 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has initiated a Phase 2 clinical trial of LX1032 , the...

EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study

Combination of Panzem(R) NCD and Avastin(R) May Slow Tumor Growth ROCKVILLE, Md., Jan. 28 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the pre...

Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome

THE WOODLANDS, Texas, Dec. 21 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ) announced today that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for LX1032, an oral drug candidate for managing gastrointest...

Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2009 Financial Results on July 28, 2009

...scovering and developing breakthrough treatments for human disease. Lexicon currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by Lexicon's research team. Lexicon has used its proprietary ...

Delcath Systems Granted Third Orphan Drug Designation

... the drug melphalan for the treatment of neuroendocrine tumors metastatic to the liver. The trial is treating patients with pancreatic islet-cell and carcinoid tumors at the National Cancer Institute in Bethesda, Maryland. Commenting on this orphan-drug designation, Richard L. Taney, President and CEO of Del...

Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer

...scovering and developing breakthrough treatments for human disease. Lexicon currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by Lexicon's research team. Lexicon has used its proprietary ...

Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week

...naging gastrointestinal symptoms associated with carcinoid syndrome . The presentations will take place at ...X1032 is entering a Phase 2 study in patients with carcinoid syndrome. For more information on these pro... candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel s...

Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009

...scovering and developing breakthrough treatments for human disease. Lexicon currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by Lexicon's research team. Lexicon has used its proprietary ...

Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online

...scovering and developing breakthrough treatments for human disease. Lexicon currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by the company's research team. The company has used its prop...

Indevus Pharmaceuticals Announces Release of 2008 Annual Report

... for hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. Contact: Michael W. Rogers EVP and Chief Financial Officer (781) 861-8444 Robin L....
Carcinoid in Biological Dictionary

Intestine

...appendix G ... structure of the intestine varies greatly in ... Small Intestine Cancer Key Terms: Adenocarcinoma , Angiosarcoma , Carcinogen , carcinoid , Leiomyosarcoma , Liposarcoma , Lymphoma , Malignant , In anatomy, the intestine is that tubular portion of the Gastrointestinal tract ... In hu...
Other Tags
(Date:8/4/2015)... ... August 04, 2015 , ... T.E.N., an information technology and security ... The ISE® Lions’ Den and Jungle Lounge 2015, which will be held from 3-6:30 ... During the event, eight emerging security vendors, known as “Gazelles,” will go head-to-head with ...
(Date:8/4/2015)... ... August 04, 2015 , ... A new ... America IT reseller channel will grow at least 6 percent in 2015, as ... pace and greater than their OEM/vendor partners. , The 2112 Group’s 2015 ...
(Date:8/4/2015)... NY (PRWEB) , ... August 04, 2015 , ... ... mortgage lender specializing in healthcare finance, announced the closing of a $118 million ... two campus health system located in Smithfield and Clayton, North Carolina. JHSC ...
(Date:8/4/2015)... ... August 04, 2015 , ... Oriental Trading Company, ... toys, novelties, and school supplies, has developed engaging and affordable teacher supplies based ... includes student rewards, classroom decorations, crafts and educational resources featuring Carle’s vibrant ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... It is ... with psoriatic disease and its uncomfortable symptoms such as dry, itching, burning or soreness ... bounce from medication to medication before they find what’s right for them. Then, what ...
Breaking Medicine News(10 mins):Health News:T.E.N. Releases Pitch Schedule for The ISE® Lions Den & Jungle Lounge 2015 2Health News:T.E.N. Releases Pitch Schedule for The ISE® Lions Den & Jungle Lounge 2015 3Health News:T.E.N. Releases Pitch Schedule for The ISE® Lions Den & Jungle Lounge 2015 4Health News:The 2112 Group Forecasts North America IT Channel to Grow At Least 6% in 2015 2Health News:The 2112 Group Forecasts North America IT Channel to Grow At Least 6% in 2015 3Health News:Armadale Capital Inc. Refinances $118 Million for Johnston Health Services Corporation 2Health News:Armadale Capital Inc. Refinances $118 Million for Johnston Health Services Corporation 3Health News:Oriental Trading Company Brings The World of Eric Carle Characters to Educators Through Classroom Supplies 2Health News:Oriental Trading Company Brings The World of Eric Carle Characters to Educators Through Classroom Supplies 3Health News:USA Medical Card Offers a Solution During National Psoriasis Awareness Month 2Health News:USA Medical Card Offers a Solution During National Psoriasis Awareness Month 3
(Date:7/31/2015)... julio de 2015 La 10 th International ... medio de BGI del 22 al 25 de octubre de 2015 ... Este año, la conferencia celebra su décimo aniversario. Desde su ... una de las reuniones anuales más influyentes del mundo en ... más dinámicas, entusiastas y mejores a nivel científico. ...
(Date:7/27/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced that Huawei has selected the Synaptics ® ... stylish smartwatch. Huawei chose the state-of-the-art ClearPad capacitive ... and highly responsive human interface qualities such as ... required a classic round watch face and Synaptics ...
(Date:7/21/2015)... July 21, 2015  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... announces that it has filed provisional patent 62/192218 ... This invention highlights next generation ... an account, but also the user using unique ...
Breaking Biology News(10 mins):La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4
Other Contents